Physician profile
Bruce E Kanengiser
NPI 1801956271
$4,597.33
in general payments reported to CMS, 2019-2025
26 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $175 · 2021: $386 · 2022: $627 · 2023: $948 · 2024: $1,197 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,198.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,116.13 | 2022-2025 | Vyzulta, Xiidra, Lotemax Sm |
| Sun Pharmaceutical Industries INC. | $756.22 | 2019-2025 | Cequa |
| Alcon Vision LLC | $475.19 | 2021-2025 | Tryptyr, Rocklatan, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $398.51 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $301.59 | 2019-2023 | |
| Revance Therapeutics, INC. | $260.81 | 2024-2025 | Daxxify |
| Oyster Point Pharma, INC. | $217.75 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $168.98 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $135.45 | 2021-2022 | |
| Allergan, INC. | $124.40 | 2020-2022 | |
| Biotissue Holdings INC. | $97.10 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $70.80 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $65.38 | 2019-2020 | |
| Thea Pharma INC. | $59.19 | 2023-2025 | Iyuzeh |
| Harrow Eye, LLC | $53.69 | 2024-2025 | Vevye |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $51.37 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Dompe US, INC. | $48.85 | 2021-2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $44.22 | 2021-2023 | Eylea |
| Amgen INC. | $36.74 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $29.46 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $17.47 | 2025 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $17.14 | 2025 | Syfovre |
| Johnson & Johnson Vision Care, INC. | $15.96 | 2023 | Acuvue |
| Eyepoint US, INC. | $13.16 | 2019 | |
| Beaver-Visitec International, INC. | $12.37 | 2021 | |
| Iridex Corporation | $9.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Kanengiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.